Thyroid disorder Board decisions

The Board granted a 40 percent disability rating for the left and right lower extremity sciatic peripheral neuropathy from April 19, 2022, but denied increased ratings for all other conditions.

The Veteran's appeals for the proposed reduction in thyroid cancer rating, discontinuance of SMC based on housebound status, earlier effective dates, and compensable rating for thyroid scar were dismissed due to being premature and not ripe for appeal.

The Board denied service connection for cervical spine and chronic fatigue syndrome, granted a 10 percent rating for chronic diarrhea, and remanded several other claims including those for left wrist neurological disorder, skin disorder, thyroid disorder, polycystic ovarian syndrome, and tension headaches.

The Board granted service connection for a liver condition and a thyroid condition, both based on exposure to water contaminants at Camp Lejeune.

The Board remands the claim for a new VA examination to address the Veteran's symptoms of cold intolerance, depression and anxiety, shortness of breath, poor hearing, and weight gain.

The Board granted service connection for hypothyroidism as a presumptively related to the Veteran's service in the Southwest Asia theater of operations during the Persian Gulf War.

The Board remands the claims for service connection for gastritis, hypothyroidism (endocrinopathy), and a skin condition to correct pre-decisional duty to assist errors.

The Board denied the Veteran's appeal for service connection for hypothyroidism as he failed to report to a scheduled VA examination without good cause.

The Board granted service connection for migraines (claimed as headaches) and denied increased ratings for hypothyroidism status post papillary carcinoma of the thyroid gland, s/p thyroidectomy, and bilateral pes planus and bilateral plantar fasciitis.

The Board remands the claim for a medical opinion to determine if the Veteran's acquired hypothyroidism is secondary to service-connected disabilities, including whether obesity was an intermediary step.

The Board remands the claim for service connection for hypothyroidism due to unverified periods of ACDUTRA and INACDUTRA, and an inadequate medical opinion.

The Board denied an earlier effective date for the grant of service connection for the Veteran's disabilities and ancillary compensation benefits, finding that August 8, 2023, was correctly assigned as the effective date.

The Board denied service connection for thyroid cancer and left side facial paralysis as the evidence did not support a finding that these conditions were related to the Veteran's active service.

The Board denied the Veteran's claim for service connection for alopecia because the condition did not manifest in service and is not otherwise related to military service. The Board remanded the claims for hypothyroidism and hyperthyroidism for additional medical opinions to clarify diagnoses and determine etiology.

The Board remands the claim for a thyroid disability to obtain an adequate medical opinion.

The appeal was dismissed as the benefit sought for service connection for diabetes mellitus type II and essential tremor, and initial compensable ratings for hypothyroidism and hypertension were withdrawn. The Board also denied a rating in excess of 10 percent based upon multiple, noncompensable, service-connected disabilities.

The Board denied an initial rating in excess of 10 percent for bilateral hearing loss and dismissed the appeal as to service connection for diabetes mellitus, high blood pressure, posttraumatic stress disorder, and thyroid issues.

The Board granted service connection for thyroid cancer, resolving reasonable doubt in favor of the Veteran.

The Board granted service connection for thyroid cancer and denied an initial rating in excess of 50 percent for PTSD, while remanding claims for service connection for erectile dysfunction, squamous cell carcinoma and malignant melanoma, and TDIU.

The Board granted service connection for hypothyroidism due to exposure to herbicide agents and remanded the claim for thyroid cancer and residuals thereof for further development.